| Literature DB >> 32943863 |
Yuanyuan Wang1, Chao Pi1, Xianhu Feng1, Yi Hou1, Ling Zhao1, Yumeng Wei1.
Abstract
Oral administration has been the most common therapeutic regimen in various diseases because of its high safety, convenience, lower costs, and high compliance of patients. However, susceptible in hostile gastrointestinal (GI) environment, many drugs show poor permeability across GI tract mucus and intestinal epithelium with poor oral absorption and limited therapeutic efficacy. In recent years, nanoparticulate drug delivery systems (NDDS) have become a hot research spot because of their unique advantages including protecting drug from premature degrading and interacting with the physiological environment, increasing intracellular penetration, and enhancing drug absorption. However, a slight change in physicochemistry of nanoparticles can significantly impact their interaction with biological pathways and alter the oral bioavailability of drugs. Hence, this review focuses on the factors affecting oral bioavailability from two aspects. On the one hand, the factors are the biochemical and physiological barriers in oral drugs delivery. On the other hand, the factors are the nanoparticle properties including size, surface properties, and shape of nanoparticles.Entities:
Keywords: nanoparticle properties; oral bioavailability; shape; size; surface properties
Year: 2020 PMID: 32943863 PMCID: PMC7455773 DOI: 10.2147/IJN.S257269
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1The benefits of using nanoparticles.
Abbreviation: GI, gastrointestinal.
Figure 2(A) The nanoparticle properties including size, surface properties, and shape of nanoparticles. (B) Schematic representation illustrating the biochemical and physiological barriers of oral drug delivery. (C) The relationship of the nanoparticle properties, oral bioavailability, and barriers in oral delivery.
Figure 3(A) Highly O-glycosylated mucin domains. Red, protein core; Green, oligosaccharides. (B) Schematic representation illustrating two types of mucus.
Thickness of Mucus in Different Parts of the Human Gastrointestinal Tract
| Mucus Membrane | Total Mucus Thickness (μm) | Ref |
|---|---|---|
| Gastric | 30–300 | [ |
| Small Intestine | 150–400 | [ |
| Ileum | 400–500 | [ |
| Colon | 30–700 | [ |
The Effect of Various Surface Modification Materials of Nanoparticles on the Oral Administration
| Material | Influential Effect | Ref |
|---|---|---|
| PEG | Increasing mucus penetration (~5 KDa) | [ |
| Reduce recognition and clearance | [ | |
| Enhance plasma circulation times | [ | |
| Promote drug accumulation | [ | |
| TA | Improve solubility of hydrophobic molecules | [ |
| Inhibitory effect of P-gp | [ | |
| Avoid gastric acid degradation | [ | |
| Polycation | Increase solubility of hydrophobic molecules | [ |
| PECs | Facilitating mucus transport | [ |
| Increasing cellular penetration | [ | |
| Lipid material | Increase the lymphatic absorption | [ |
| [ | ||
| Specific ligands | Increasing cellular uptake | [ |
Abbreviations: PEG, ploy(ethylene glycol); TA, tannic acid; PECs; polyelectrolyte complexes; P-gp, P-glycoprotein.
Figure 4Structural formula of partial materials containing hydrophilic groups.
The Different Internalization Pathways Corresponding to Different Cells and the Main Shapes Associated with Them
| Cellular Mechanism | Cell Type | Nanoparticle Shape | Ref |
|---|---|---|---|
| Phagocytosis | Macrophages | Large ARs | [ |
| Monocytes | |||
| Dendritic cells | |||
| Natural killer cells | |||
| Neutrophils | |||
| Macropinocytosis | Endothelial cells | [ | |
| Epithelial cells | |||
| Clathrin-mediated endocytosis | Endothelial cells | Sphere-shaped particles | [ |
| Caveolin-mediated endocytosis | The capillary endothelium | Large ARs | [ |
| Type I epithelial cells | |||
| Muscle cells | |||
| Fibroblasts |
Abbreviation: AR, aspect ratio.